Corvus Pharmaceuticals (CRVS) Restructuring Costs (2024 - 2026)

Corvus Pharmaceuticals (CRVS) posted quarterly Restructuring Costs of $1.9 million for Q1 2026, up 103.38% year-over-year from $946000.0 in Q1 2025, and up 211.83% quarter-over-quarter from $617000.0 in Q3 2025.

Corvus Pharmaceuticals (CRVS) Restructuring Costs (2024 - 2026) Analysis & Trends

Corvus Pharmaceuticals' Restructuring Costs history runs 3 years deep, the most recent figure standing at $1.9 million for Q1 2026.

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr)
1 Vertex Pharmaceuticals 128.13 Bn 120.28 Bn 2.84 Bn
2 Regeneron Pharmaceuticals 112.33 Bn 104.33 Bn 3.93 Bn
3 Argenx Se 53.24 Bn 48.05 Bn 1.41 Bn
4 Revolution Medicines 43.64 Bn 43.64 Bn -
5 BeOne Medicines 39.27 Bn 34.17 Bn 1.53 Bn
6 MindWalk Holdings 35.32 Bn 35.31 Bn 1.82 Bn
7 Royalty Pharma 33.72 Bn 35.84 Bn -
8 Alnylam Pharmaceuticals 30.58 Bn 27.27 Bn 992.69 Mn
9 Insmed 27.01 Bn 25.85 Bn 358.27 Mn
10 Corvus Pharmaceuticals 1.25 Bn 1.04 Bn -

Historic Data

Download Data
DateValue
Jun 30, 2026 4.15 Mn
Mar 31, 2026 1.92 Mn
Sep 30, 2025 617,000.00
Jun 30, 2025 848,000.00
Mar 31, 2025 946,000.00
Sep 30, 2024 776,000.00
Jun 30, 2024 551,000.00
Mar 31, 2024 994,000.00